Article
Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.
Pancreas - 1 Feb 2018
Herman Joseph M, Jabbour Salma K, Lin Steven H, Deek Matthew P, Hsu Charles C, Fishman Elliot K, Kim Sinae, Cameron John L, Chekmareva Marina, Laheru Daniel A, Narang Amol K, Pawlik Timothy M, Hruban Ralph H, Wolfgang Christopher L, Iacobuzio-Donahue Christine A
Abstract excerpt
OBJECTIVES: The tumor suppressor gene SMAD4 (DPC4) is genetically inactivated in approximately half of pancreatic ductal adenocarcinomas (PDAs). We examined whether Smad4 tumor status was associated with outcomes after adjuvant chemoradiation (CRT) for resected PDAs. METHODS: Patients treated with adjuvant CRT were identified (N = 145). Smad4 status was determined by immunolabeling and graded as intact or lost....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.